Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CTSD | P07339 | 2/20 | 0.46 |
| ▸ | CTSE | P14091 | 1/20 | 0.46 |
| ▸ | PGC | P20142 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8248846 | 1.00 | SPPL2A (0.51) | SPPL2ACYP3A4CTSDCTSEPGC | |
| SCHEMBL12435857 | 1.00 | SPPL2A (0.51) | SPPL2ACYP3A4CTSDCTSEPGC | |
| SCHEMBL13480554 | 0.94 | SPPL2A (0.55) | SPPL2ACYP3A4CTSDMLNRABCB11 | |
| SCHEMBL12435841 | 0.93 | CTSD (0.45) | SPPL2ACYP3A4CTSDCTSEPGC | |
| SCHEMBL12434864 | 0.93 | CTSD (0.45) | SPPL2ACYP3A4CTSDCTSEPGC | |
| SCHEMBL8245621 | 0.93 | CTSD (0.45) | SPPL2ACYP3A4CTSDCTSEPGC | |
| SCHEMBL12434835 | 0.91 | SPPL2A (0.53) | SPPL2ACYP3A4CTSDMLNRABCB11 | |
| SCHEMBL8238981 | 0.91 | SPPL2A (0.53) | SPPL2ACYP3A4CTSDMLNRABCB11 | |
| SCHEMBL12435818 | 0.91 | CTSD (0.44) | SPPL2ACYP3A4CTSDCTSEPGC | |
| SCHEMBL8245611 | 0.91 | CTSD (0.44) | SPPL2ACYP3A4CTSDCTSEPGC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178092-A1 | HIV-1 Protease Inhibitors | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178092-A1 | HIV-1 Protease Inhibitors | SERPINB1, PRSS1, TMPRSS4 | SPPL2A 348/4885CYP3A4 1247/4885CTSD 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.